தண்டு செல் மாற்று ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தண்டு செல் மாற்று ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தண்டு செல் மாற்று ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Large Gene panel helpful in identifying cancer-causing genes


Large Gene panel helpful in identifying cancer-causing genes
ANI |
Updated: Feb 06, 2021 14:14 IST
Washington [US], February 6 (ANI): Researchers during a recent study have found a gene panel that includes all genes known to potentially cause cancer. This can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML.
The 523-gene panel, which looks about 10 times the number of cancer-causing genes, developed by San Diego-based biotech company Illumina, is currently used to diagnose and fine-tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia. The investigators reported in the journal PLOS ONE. ....

United States , Ravindra Kolhe , Vamsi Kota , Au Health , Stem Cell Transplant Program , Molecular Laboratory , Department Of Pathology , Georgia Cancer Center , College Of Georgia At Augusta University , National Comprehensive Cancer Network , San Diego Based , Medical College , Bone Marrow , Georgia Esoteric , Gene Panel , Cancer Causing Genes , Latest Science Related News , ஒன்றுபட்டது மாநிலங்களில் , ரவின்ற கொள்ே , வம்சி கோட்டா , ஆ ஆரோக்கியம் , தண்டு செல் மாற்று ப்ரோக்ர்யாம் , மூலக்கூறு ஆய்வகம் , துறை ஆஃப் நோயியல் , ஜார்ஜியா புற்றுநோய் மையம் , கல்லூரி ஆஃப் ஜார்ஜியா இல் அகஸ்டா பல்கலைக்கழகம் ,

Larger panel finds more gene mutations, treatment targets for leukemia


Credit: Kim Ratliff, Augusta University Photographer
AUGUSTA, Ga. (Feb. 1, 2020) - A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report.
The 523-gene panel, developed by San Diego-based biotech company Illumina, which includes all genes known to potentially cause cancer, can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML, the investigators report in the journal
PLOS ONE.
Identifying more genetic mutations in an individual s cancer also enables more targeted treatment for that patient, they say. That includes finding mutations not previously associated with their cancer type, which opens the door to using drugs targeting those mutations that have traditionally been used against other cancers. ....

United States , Ravindra Kolhe , Vamsi Kota , Au Health , Stem Cell Transplant Program , Molecular Laboratory , Department Of Pathology , Georgia Cancer Center , College Of Georgia At Augusta University , National Comprehensive Cancer Network , San Diego Based , Medical College , Bone Marrow , Georgia Esoteric , Medicine Health , ஒன்றுபட்டது மாநிலங்களில் , ரவின்ற கொள்ே , வம்சி கோட்டா , ஆ ஆரோக்கியம் , தண்டு செல் மாற்று ப்ரோக்ர்யாம் , மூலக்கூறு ஆய்வகம் , துறை ஆஃப் நோயியல் , ஜார்ஜியா புற்றுநோய் மையம் , கல்லூரி ஆஃப் ஜார்ஜியா இல் அகஸ்டா பல்கலைக்கழகம் , தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் , சான் டியாகோ அடிப்படையிலானது ,

Dr. Han Myint Appointed as NextCure's Chief Medical Officer Nasdaq:NXTC


Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
January 14, 2021 16:05 ET
| Source:
NextCure
NextCure
Beltsville, Maryland, UNITED STATES
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc. ....

United States , Rush University Medical Center , United Kingdom , Michael Richman , Ethan Myint , Celgenea Bristol Myers Squibb Company , Global Medical Affairs , American College Of Physicians , Stem Cell Transplant Program , University Of Colorado , Institute Of Medicine , Neximmune Inc , Nextcure Inc , Bristol Myers Squibb Company , Vice President , Myeloid Diseases Lead , Internal Medicine , Royal Colleges , American College , Nasdaq Nxtc , ஒன்றுபட்டது மாநிலங்களில் , அவசரம் பல்கலைக்கழகம் மருத்துவ மையம் , ஒன்றுபட்டது கிஂக்டம் , மைக்கேல் பணக்காரன் , ஹான் மியண்ட் , உலகளாவிய மருத்துவ வாழ்க்கைத்தொழில்கள் ,

Parade held for Oregon nurse with 40+ years of service


Nurse friends and family had a parade to honor Carla Lee, who is retiring in January 2021.
Author: KGW Staff
Updated: 4:51 PM EST January 4, 2021
PORTLAND, Ore. An Oregon nurse of more than 40 years is getting a special sendoff for her retirement.
Nurse friends and family had a parade for Carla Lee, a registered nurse who worked at Legacy Emanuel and Good Samaritan Medical Center.
Her supervisor, Mika Sunago, organized the parade, with a group meeting in NE Portland Saturday morning to drive past Lee s house.
Lee started her nursing career in 1976. She began work at Legacy in 1981 in the oncology unit. ....

United States , Mika Sunago , Carla Lee , Good Samaritan Medical Center , Stem Cell Transplant Program , Legacy Emanuel , Good Samaritan Medical , Stem Cell Transplant , ஒன்றுபட்டது மாநிலங்களில் , கார்லா லீ , நல்ல சமாரியன் மருத்துவ மையம் , தண்டு செல் மாற்று ப்ரோக்ர்யாம் , மரபு இமானுவேல் , நல்ல சமாரியன் மருத்துவ , தண்டு செல் மாற்று ,